Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats

Bülbül, Mehmet; Sinen, Osman; Özkan, Ayşe; Aslan, Mutay; Ağar, Ayşel

doi:10.1016/j.expneurol.2019.02.015

Cited by 18 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the positive control L-DOPA, NPS dose-dependently attenuated motor impairments assessed in the rotarod test in mice [ 12 ]. The effects of NPS in counteracting motor dysfunction of PD were recently confirmed by Bülbül et al [ 11 ] and Sinen et al [ 14 ] in rats. For instance, acute and repeated icv injection of NPS (10 and 1 nmol, respectively) significantly improved 6-OHDA-induced hypolocomotion and motor incoordination [ 11 , 14 ] as well as restored reduction in nigral dopamine release [ 11 ].…”

Section: Behavioral Effects Of Neuropeptide S: Implications For Parkinson Diseasementioning

confidence: 74%

“…More recently, a double immunofluorescence labeling study showed that NPSR is intensely coexpressed with TH-positive neurons in the substantia nigra [ 11 ], thus reinforcing the modulatory role of NPSR signaling in controlling dopamine transmission in the basal ganglia. The basal ganglia are particularly relevant for motor programming and execution [ 70 ].…”

Section: Behavioral Effects Of Neuropeptide S: Implications For Parkinson Diseasementioning

confidence: 98%

“…Considering the focus of this review on the NPS system as an innovative therapeutic target to treat Parkinson disease (PD), it is essential to emphasize that NPSR mRNA is expressed in dopaminergic areas, such as the substantia nigra pars compacta and ventral tegmental area [ 6 , 7 ]. Recently, a double immunofluorescence labeling study showed that NPSR is coexpressed with tyrosine hydroxylase (TH)-positive neurons in the substantia nigra [ 11 ]. Additionally, noticeable c-Fos expression was observed in TH-positive cells in the substantia nigra after acute icv administration of NPS (10 nmol), but not vehicle [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, a double immunofluorescence labeling study showed that NPSR is coexpressed with tyrosine hydroxylase (TH)-positive neurons in the substantia nigra [ 11 ]. Additionally, noticeable c-Fos expression was observed in TH-positive cells in the substantia nigra after acute icv administration of NPS (10 nmol), but not vehicle [ 11 ]. Altogether, these findings suggest a potential role for the NPS system in the modulation of nigral dopaminergic transmission.…”

Section: Introductionmentioning

confidence: 99%

“…Several in vivo studies replicated these stimulatory actions in rodents (see Table 1 ), and the putative mechanisms were partially described. More recently, studies showing beneficial effects of NPS in counteracting behavioral and neurobiological aspects of PD in rodents have been published [ 11 , 12 , 13 , 14 ]. This review aims to briefly present epidemiological and pathophysiological aspects of PD and to discuss the available pharmacotherapy for this neurodegenerative disease.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease

et al. 2021

View full text Add to dashboard Cite

Parkinson disease (PD) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. Patients suffering from PD develop severe motor dysfunctions and a myriad of non-motor symptoms. The treatment mainly consists of increasing central dopaminergic neurotransmission and alleviating motor symptoms, thus promoting severe side effects without modifying the disease’s progress. A growing body of evidence suggests a close relationship between neuropeptide S (NPS) and its receptor (NPSR) system in PD: (i) double immunofluorescence labeling studies showed that NPSR is expressed in the nigral tyrosine hydroxylase (TH)-positive neurons; (ii) central administration of NPS increases spontaneous locomotion in naïve rodents; (iii) central administration of NPS ameliorates motor and nonmotor dysfunctions in animal models of PD; (iv) microdialysis studies showed that NPS stimulates dopamine release in naïve and parkinsonian rodents; (v) central injection of NPS decreases oxidative damage to proteins and lipids in the rodent brain; and, (vi) 7 days of central administration of NPS protects from the progressive loss of nigral TH-positive cells in parkinsonian rats. Taken together, the NPS/NPSR system seems to be an emerging therapeutic strategy for alleviating motor and non-motor dysfunctions of PD and, possibly, for slowing disease progress.

show abstract

Section: Behavioral Effects Of Neuropeptide S: Implications For Parkinson Diseasementioning

confidence: 74%

Section: Behavioral Effects Of Neuropeptide S: Implications For Parkinson Diseasementioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

Effects of adropin on learning and memory in rats tested in the Morris water maze

et al. 2021

Self Cite

View full text Add to dashboard Cite

Adropin is a secreted peptide, which is composed of 43 amino acids and shows an effective role in regulating energy metabolism and insulin resistance. Motor coordination and locomotor activity were improved by adropin in the cerebellum. However, it is not known whether adropin administration has an effect on spatial learning and memory. In this study, we investigated the effect of adropin on spatial learning and memory and characterized the biochemical properties of adropin in the hippocampus. Thirty male Sprague–Dawley rats were randomly divided into two groups as control and adropin groups. The control group received 0.9% NaCl intracerebroventricular for 6 days, while the adropin groups received 1 nmol of adropin dissolved in 0.9% NaCl (for 6 days). The Morris water maze, Y maze, and object location recognition tests were performed to evaluate learning and memory. Also, the locomotor activity tests were measured to assess the motor function. The expression of Akt, phospho‐Akt, CREB, phospho‐CREB, Erk1/2, phospho‐Erk1/2, glycogen synthase kinase 3 β (GSK3β), phospho‐GSK3β, brain‐derived neurotrophic factor (BDNF), and N‐methyl‐d‐aspartate receptor NR2B subunit were determined in the hippocampal tissues by using western blot. Behavior tests showed that adropin significantly increase spatial memory performance. Meanwhile, the western blot analyses revealed that the phosphorylated form of the Akt and CREB were enhanced with adropin administration in the hippocampus. Also, the expression of BDNF showed an enhancement in adropin group in comparison to the control group. In conclusion, we have shown for the first time that adropin exerts its enhancing effect on spatial memory capacity through Akt/CREB/BDNF signaling pathways.

show abstract

Recent advances in mass spectrometry analysis of neuropeptides

Phetsanthad

et al. 2021

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Due to their involvement in numerous biochemical pathways, neuropeptides have been the focus of many recent research studies. Unfortunately, classic analytical methods, such as western blots and enzyme‐linked immunosorbent assays, are extremely limited in terms of global investigations, leading researchers to search for more advanced techniques capable of probing the entire neuropeptidome of an organism. With recent technological advances, mass spectrometry (MS) has provided methodology to gain global knowledge of a neuropeptidome on a spatial, temporal, and quantitative level. This review will cover key considerations for the analysis of neuropeptides by MS, including sample preparation strategies, instrumental advances for identification, structural characterization, and imaging; insightful functional studies; and newly developed absolute and relative quantitation strategies. While many discoveries have been made with MS, the methodology is still in its infancy. Many of the current challenges and areas that need development will also be highlighted in this review.

show abstract

Central neuropeptide-S treatment improves neurofunctions of 6-OHDA-induced Parkinsonian rats

Cited by 18 publications

References 45 publications

Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease

Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease

Effects of adropin on learning and memory in rats tested in the Morris water maze

Recent advances in mass spectrometry analysis of neuropeptides

Contact Info

Product

Resources

About